top of page

Healthcare


Servier's $2.5bn Acquisition of Day One Biopharmaceuticals
By Rakan Aqrouq, Krissa Mou, Scarlet Park, and Terry Zhang (University of British Columbia); Amin Ouamar, Gilles Michaud, and Marc Bellon (HEC Paris). Photo: Piron Guillame Overview of the deal Acquirer: Laboratoires Servier Target: Day One Biopharmaceuticals Implied Equity Value: $2.5 bn Total Transaction Size: $2.5 bn Closed date: Announced on March 6th, 2026. Expected to close in Q2 2026 Target advisor: Centerview Partners, (financial), Fenwick & West, Wilson Sonsini Goodr
Apr 29


Generate Biomedicines’ IPO
By Shahmir Ahmed, Alp Ceylan, and Francesco del Sesto (Bocconi University); Alvaro Aguilar De Nalda (ESADE); Diana Usova, Dylan Stiassny, Oli Cedar, Obianuju Okafor (University of Bristol) Photo: Volodymyr Hryshchenko (Unsplash) Summary of IPO As the pharmaceutical industry looks to artificial intelligence to accelerate drug discovery, Generate Biomedicines are positioning themselves as a force to be reckoned with in this growing market. Through what the company has dubbed “G
Mar 23


BillionToOne’s IPO
By Kush Mahawar, Lexi Xiao, Sean Yeow and Joe Colton (University of Oxford); Alvaro Aguilar De Nalda (ESADE); Cooper Thompson, Charlie Mercuri, Daniel Blitenthall and Aikie Davoren (University of Melbourne) Photo: Ashraful Islam (Unsplash) Summary of IPO BillionToOne, a molecular diagnostics company, raised $314 million on November 6, 2025, in an upsized initial public offering that stands as one of the largest MedTech IPOs of the year by capital raised. Despite the headwinds
Feb 18


Boston Scientific’s $14.5bn Acquisition of Penumbra
By Julianna Zelnhefer, Alex Svanidze, Ryan Leo, and Ava Singer (Boston University); Alvaro Aguilar De Nalda (ESADE); Haci Eren Sidar, Mustafa Arda Sis, Muthu Ramanathan, Josh Lai (University of Nottingham) Photo: Piron Gillaume (Unsplash) Overview of the deal Acquirer: Boston Scientific Target: Penumbra Implied Equity Value : $13.4 billion Total Transaction Size: $14.5 billion Closing Date: N/A Target Advisor: Perella Weinberg Partners (financial), Wardwell LL (legal) A
Feb 16


Cencora’s $7.4bn Acquisition of OneOncology
By Krissa Mou, Scarlet Park, Rakan Aqrouq, and Terry Zhang (University of British Columbia); Alvaro Aguilar De Nalda (ESADE); Utku Kaya, Omar Kanaa, Nayoung Kim, Harvey Han and Tomiwa Oshai (King’s College London) Photo: Christina Victoria Craft (Unsplash) Overview of the deal Acquirer: Cencora Target: OneOncology Implied Equity Value: $6 billion Total Transaction Size: $7.4 billion Closed date: End of 2026 Q1 Target advisor: Debevoise & Plimpton LLP (legal) Acquirer ad
Feb 4


Merck's $9.2bn Acquisition of Cidara Therapeutics
By Arthus Marande, Namien Koné, Olivia Riera Ripoll, Nehir Yanmaz, (ESCP), Diana Usova, Oliver Cedar, Dylan Stiassny, Obianuju Okafor (University of Bristol) Photo: Akram Huseyn (Unsplash) Overview of the deal Acquirer: Merck Target: Cidara Therapeutics Total Transaction Size: $9.2 Billion Closed date: Expected First Quarter 2026 Target advisor(s): Evercore and Goldman Sachs & Co (financial), Cooley (legal) Acquirer advisor(s): BofA Securities (financial), Gibson Dunn (
Jan 14


Kimberly-Clark's $48.7bn Acquisition of Kenvue
By Roman Annan, Sophie Zhang, Joey Zhang, and Amani Dhillon (Columbia University), Rasmus Sjögren, Nikolas Kakona, Alexander Henje Scott, and Haris Jasarevic (Stockholm School of Economics) Photo: Khuc Le Thanh Danh (Unsplash) Overview of the deal Acquirer : Kimberly-Clark Corporation Target : Kenvue Inc. Implied Equity Value : $40.32 B Total Transaction Size : $48.7 B Closed date : H2 2026 (Estimated, legal issues pending) Target advisor : Centerview Partners LLC & Goldman
Jan 12


Pfizer’s $10bn Acquisition of Metsera
By Freya Zhang, Akshi Bansal, Chak Li, Jacky Chan, Sharon Liu (HKUST); Anastasia Malikova, Dennis Malaj, Gauri Khanna, Sarah Lee (LSE) Photo: Laurynas Me (Unsplash) Overview of the deal Acquirer: Pfizer Inc. Target: Metsera Inc. Implied Equity Value : ~$9.2 billion (~7 billion cash upfront & up to ~$2.2 billion in contingent milestone payments) Total Transaction Size: Up to US$10 billion Closing Date: 13th November 2025 Target Advisor: Goldman Sachs & Co.LLC , Guggenhei
Dec 11, 2025


Blackstone and TPG's $18.3bn Acquisition of Hologic
By Arthus Marande, Christopher Putnis, Namien Koné, Mattia Colombo (ESCP); Freya ZHANG, Jacky CHAN, Sharon Liu, Akshi Bansal, Chak Li (HKUST). Photo: Khanh Nguyen Overview of the deal Acquirer: Blackstone, TPG, and other minorities (ADIA, GIC) Target: Hologic, Inc. Implied Equity Value: $17.67bn Total Transaction Size: $18.3bn (EV) Closed date: Pending; expected H1 2026 (45-day go-shop in the agreement) Target advisor: Citi (Financial); Kirkland & Ellis (Legal); Ropes & G
Dec 1, 2025


Novo Nordisk's $5.2bn Acquisition of Akero
By Kush Mahawar, Lexi Xiao, Joe Colton, Sean Yeow (University of Oxford); Diana Usova, Dylan Stiassny, Oli Cedar, Obianuju Okafor (University of Bristol) Photo: Simone van der Koelen Deal Overview Acquirer : Novo Nordisk Target : Akero Therapeutics Total Transaction Size : $5.2bn (including CVR) Closed Date : Expected Q4 2025 Target Advisors : Morgan Stanley and J.P. Morgan (Financial); Kirkland & Ellis (Legal) Acquirer Advisors : Bank of America (Financial); Ropes & Grey (Le
Nov 24, 2025


Mallinckrodt Pharmaceuticals' $6.7bn Merger with Endo
By Edward Fung, Freya Zhang, Henry Yum, Sanghyeon Kim (HKUST); Moritz Ibe, Avital Anoff, Lukas Ehrlich, Annant Bhargava (University of St...
May 22, 2025


Siemens' $5.1bn Acquisition of Dotmatics
By Giorgio Goretti, Marco Morchio, Carlotta Nardello (ESADE); James Searle, Ben Motamed, Greg Dargue, Cameron Hansell (Durham University)...
May 15, 2025


Stryker’s $4.9bn acquisition of Inari Medical
By Anna Chesca, Aditya Tatwawadi, Ahyaan Malik, and Alex Scothorn (University of Cambridge); Edward Mazin, Charlie Hogshire, Caden Viehe,...
Feb 27, 2025


Siemens Healthineers’ $200mn Acquisition of Novartis’ Advanced Accelerator Applications Division
By Pierre Caye, Giuliana Vadacchino, Jules Donzelot, Mathis Grandchamp, Alexander Megrelis, Loïc Meunier (McGill University), Devon...
Sep 16, 2024


Yellow Wood’s $512mn Acquisition of Chapstick
By Dhruv Kotecha, Keerthi Komati, Ryan Luk and Aviral Jain (University of Nottingham) ; Varun Vinay Iyengar, Rui Lee and Ardia Daniswara,...
Mar 4, 2024


Novo Holding’s $16.5bn Acquisition of Catalent
By Ahaan Roychowdhury, Shyam Patra, Dimos Kamposiouras, Krish Raj (UCL) ; Melvin Bergeret, Arthur Delfour, Axel Nkam, Victor Zheng and...
Feb 24, 2024


GSK’s $1.4bn acquisition of Aiolos Bio
By Enrique Perez-Hernandez, Tarvo Simons, Taha Yassine, Michael Joachim ten Eicken and Juan Pelaez (IE University) ; Sean Millar, Annant...
Feb 8, 2024


Roche’s $2.7bn Acquisition of Carmot Therapeutics
By Rafi Glass, Yana Zharkova, James Searle, Guy Collins, Marcin Wolniewicz and Ruiting Yi (Durham University) ; Edward Mazin, Lars...
Dec 15, 2023


Healthpeak’s $2.64bn merger with Physicians Realty
By Varun Vinay Iyengar, Rui Lee and Ardia Daniswara (King’s College London) ; Melvin Bergeret, Arthur Delfour, Axel Nkam and Victor Zheng...
Nov 29, 2023


Roche's $7.1bn acquisition of Telavant
By Sean Millar, Ben Preece, Moritz Ibe, and Junqi Wang (University of St Andrews) ; Sam Oberly, Julia Weinrod, Yuyu Huang, Talia...
Nov 23, 2023


Merck’s $10.8bn Acquisition of Prometheus Biosciences
By Athean Myat, Coby Lai, Michelle Liu, Carden Olsson and Angelina Gart (Cornell University) Photo: Sangharsh Lohakare (Unsplash)...
May 4, 2023


Sanofi’s $2.9bn Acquisition of Provention Bio
By Mathilde Heibig, Pierre Six, and Jingying Liu (HEC Paris), Athean Myat, Ana Almeida, Angelina Gart, Coby Lai, Michelle Liu, and Carden...
Mar 29, 2023
bottom of page
